Other Pipelines

We set development priorities based on market size, unmet medical needs, technical differentiation and development feasibility, and continually discover and develop competitive follow-on programs with the goal of early-stage out-licensing.

CU71
Route
Oral
Indication
Neurodegenerative diseases
Development approach
Development of therapies addressing endothelial dysfunction and blood–brain barrier (BBB) dysfunction
Development status
Discovery
CU72
Route
Oral
Indication
Idiopathic pulmonary fibrosis
Development approach
AI-driven development of next-generation therapies addressing unmet needs in current treatments for idiopathic pulmonary fibrosis
Development status
DiscoverySelected in 2026 for the Ministry of SMEs and Startups’ collaborative pharmaceutical–bio venture R&D program
CU73
Route
Oral
Indication
Thrombotic diseases
Development approach
Development of novel oral small-molecule therapies for thrombotic diseases
Development status
Discovery
CU03
Route
Oral
Indication
Age-related macular degeneration
Development approach
A multi-target therapeutic approach to macular degeneration
Development status
Korea Phase 2a clinical study report (CSR) received (2022.01)
CU104
Route
Oral
Indication
Ulcerative colitis
Development approach
Indication expansion of CU06 for ulcerative colitis
Development status
Phase 2a IND approvals in the U.S. and EuropeDevelopment strategy under review in alignment with CU06 global partnering
CU106
Route
Oral
Indication
Immuno-oncology combination therapy
Development approach
Indication expansion of CU06 for combination with cancer immunotherapies
Development status
Phase 1 completed in the U.S.Development strategy under review in alignment with CU06 global partnering
MT-105
Route
Intravenous
Indication
Inflammatory bowel disease
Development approach
Development of novel therapies targeting multiple pathological factors in inflammatory bowel disease
Development status
Discovery
MT-202
Route
Intravenous · Bispecific antibody
Indication
Ischemic stroke
Development approach
Combining PDI inhibition and Tie2 activation to inhibit thrombus formation and protect the vascular endothelium
Development status
Discovery
MT-40X
Route
Intravenous
Indication
Cancer
Development approach
Development approach to be disclosed
Development status
Discovery
MT-501
Route
Intravenous · Bispecific antibody
Indication
Vasculitis
Development approach
Tie2 activation and C5-axis inhibition for vascular stabilization and inflammation control
Development status
Discovery
CP01
Route
Oral
Indication
Canine chronic kidney disease (CKD)
Development approach
An endothelial dysfunction blocker for chronic kidney disease in dogs
Development status
Phase 3 study in dogs ongoing in Korea
CP02
Route
Oral
Indication
Feline chronic kidney disease (CKD)
Development approach
An endothelial dysfunction blocker for chronic kidney disease in cats
Development status
Discovery